ADVERTISEMENT
Abstracts
P036
Patient Outcomes In Those Diagnosed With Multiple Myeloma Over A 5-Year Period In India
Introduction:
Multiple myeloma (MM) is the second most common hematological malignancy worldwide. The treatment of MM is induction therapy followed by an autologous stem cell transplant (ASCT). In developing countries such as India, affordability is a significant hurdle patients face as the cost of ASCT is very high. Because of wide gaps individual economic gain, lack of healthcare infrastructure, especially in rural areas, and the lack of access to novel drugs, the treatment of MM remains a challenge in India.
Methods:
70 newly diagnosed MM patients were followed over 5‚Äâyears to look for the initial stage of diagnosis, affordability of treatment, and the overall outcome of patients.
Results:
The median age of diagnosis for both groups was 55‚Äâyears (38-88), the male to female ratio was 1.4:1, and IgG myeloma was the most common type seen in 77% of patients. The Revised International Staging Syndrome (ISS) at the time of diagnosis was ISS 1 (34%), ISS 2 (31%), and ISS 3 (35%). 31 patients were from urban areas, and 39 were from rural areas. Most patients from rural areas were in stages 2 and 3 at onset, whereas most of the urban population was in ISS 1.
Of the 44 patients who were treated with chemotherapy 29 (66%) had a partial response to treatment, 7 (16%) had a complete response to treatment, and 8 (18%) patients did not respond to treatment. During the initial first year of the study, 6 patients (13%) in the group who elected to receive treatment passed away. 8 patients of the 44 (18%) could not afford treatment after the initial year and elected not to pursue treatment, and 2 (5%) patients stopped treatment after 2‚Äâyears, all of whom were from the low-income rural group. The overall survival of the original 45 patients after 5‚Äâyears of the study was 54% (24 patients survived).
Multiple myeloma (MM) is the second most common hematological malignancy worldwide. The treatment of MM is induction therapy followed by an autologous stem cell transplant (ASCT). In developing countries such as India, affordability is a significant hurdle patients face as the cost of ASCT is very high. Because of wide gaps individual economic gain, lack of healthcare infrastructure, especially in rural areas, and the lack of access to novel drugs, the treatment of MM remains a challenge in India.
Methods:
70 newly diagnosed MM patients were followed over 5‚Äâyears to look for the initial stage of diagnosis, affordability of treatment, and the overall outcome of patients.
Results:
The median age of diagnosis for both groups was 55‚Äâyears (38-88), the male to female ratio was 1.4:1, and IgG myeloma was the most common type seen in 77% of patients. The Revised International Staging Syndrome (ISS) at the time of diagnosis was ISS 1 (34%), ISS 2 (31%), and ISS 3 (35%). 31 patients were from urban areas, and 39 were from rural areas. Most patients from rural areas were in stages 2 and 3 at onset, whereas most of the urban population was in ISS 1.
Of the 44 patients who were treated with chemotherapy 29 (66%) had a partial response to treatment, 7 (16%) had a complete response to treatment, and 8 (18%) patients did not respond to treatment. During the initial first year of the study, 6 patients (13%) in the group who elected to receive treatment passed away. 8 patients of the 44 (18%) could not afford treatment after the initial year and elected not to pursue treatment, and 2 (5%) patients stopped treatment after 2‚Äâyears, all of whom were from the low-income rural group. The overall survival of the original 45 patients after 5‚Äâyears of the study was 54% (24 patients survived).
Publisher
John Wiley & Sons; Hoboken, USA
Source Journal
American Journal of Hematology
2022 Wiley Periodicals LLC.
